Appendix D
Chronology of Important Events Regarding Vaccine Safety

Year

Vaccine Licensure

Legislation and/or Policy Statements

IOM Reports on Vaccine Safety

1955

Inactivated poliomyelitis vaccine (IPV) available

 

 

1963

Oral poliomyelitis vaccine (OPV) available, replaces IPV

Measles vaccine available

 

 

1967

Mumps vaccine available

 

 

1969

Rubella vaccine available

 

 

1971

Measles-Mumps-Rubella

(MMR) vaccine available

 

 

1977

 

Mumps vaccination recommended

Evaluation of Poliomyelitis Vaccines

1979

Current formulation of rubella vaccine available, replaces earlier versions

 

 

1982

Plasma-derived hepatitis B vaccine available

 

 



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 187
Immunization Safety Review: Vaccines and Autism Appendix D Chronology of Important Events Regarding Vaccine Safety Year Vaccine Licensure Legislation and/or Policy Statements IOM Reports on Vaccine Safety 1955 Inactivated poliomyelitis vaccine (IPV) available     1963 Oral poliomyelitis vaccine (OPV) available, replaces IPV Measles vaccine available     1967 Mumps vaccine available     1969 Rubella vaccine available     1971 Measles-Mumps-Rubella (MMR) vaccine available     1977   Mumps vaccination recommended Evaluation of Poliomyelitis Vaccines 1979 Current formulation of rubella vaccine available, replaces earlier versions     1982 Plasma-derived hepatitis B vaccine available    

OCR for page 187
Immunization Safety Review: Vaccines and Autism Year Vaccine Licensure Legislation and/or Policy Statements IOM Reports on Vaccine Safety 1985 Hib vaccine licensed for children >15 months     1986   Congress passes P.L. 99-660, the National Childhood Vaccine Injury Act (introduced in 1984) calls for: est. of NVPO est. of NVAC est. of VICP est. of ACCV IOM review of (1) pertussis and rubella, (2) routine child vaccines   1988     Evaluation of Poliomyelitis Vaccine Policy Options 1990 Two Hib conjugate vaccines licensed for use beginning at 2 months     1991 Acellular pertussis component licensed for the 4th and 5th doses of the 5-part DTP series in ACEL-IMUNE Hepatitis B recommended by ACIP for addition to childhood immunization schedule ACIP recommends Hib be added to childhood immunization schedule Adverse Effects of Pertussis and Rubella Vaccines 1992 Acellular pertussis component licensed for the 4th and 5th doses of the 5-part DTP series in Tripedia Hepatitis B vaccine: Added universal vaccination for all infants, high-risk adolescents (e.g., IV drug users, persons with multiple sex partners)   1993 Combined DTP and Hib vaccine (Tetramune) licensed    

OCR for page 187
Immunization Safety Review: Vaccines and Autism Year Vaccine Licensure Legislation and/or Policy Statements IOM Reports on Vaccine Safety 1994     Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality DPT and Chronic Nervous System Dysfunction: A New Analysis 1995 Varicella virus vaccine available (Varivax)     1996 DTaP vaccine licensed for first three doses given in infancy (Tripedia and ACEL-IMUNE were previously licensed for only the 4th and 5th doses). ACIP recommends using IPV for the first 2 polio vaccinations, followed by OPV for remaining doses. Intended to be a transitional schedule for 3–5 years until an all-IPV series is available ACIP recommends children 12 months to 12 years receive Varicella vaccine Options for Poliomyelitis Vaccinations in the United States: Workshop Summary 1997 Additional DTaP vaccine (Infanrix) licensed for first 4 doses of 5-part series ACIP recommends DTaP in place of DTP Vaccine Safety Forum: Summary of Two Workshops Risk Communication and Vaccination: Workshop Summary 1998 Additional DTaP vaccine (Certiva) licensed for first 4 doses of 5-part series ACIP updates MMR recommendation, encouraging use of the combined MMR vaccine  

OCR for page 187
Immunization Safety Review: Vaccines and Autism Year Vaccine Licensure Legislation and/or Policy Statements IOM Reports on Vaccine Safety 1999   ACIP updates varicella vaccine recommendation, requiring immunity for child care and school entry ACIP recommends an all-IPV schedule to begin January 2000 to prevent cases of vaccine-associated paralytic polio AAP and PHS recommend removal of thimerosal from vaccines Also recommended postponement of hepatitis B vaccine from birth to 2-6 months for infants of hepatitis B surface antigen-negative mothers     Additional supply of thimerosal-free hepatitis B vaccine made available MMWR notifies readers of the availability of a thimerosal-free hepatitis B vaccine, enabling the resumption of the birth dose   2000 Pneumococcal vaccine for infants and young children licensed (Prevnar) ACIP recommends pneumococcal vaccination for all children 2-23 months, and at-risk children 24-59 months (e.g., immunocompromised)   2001   October: ACIP drafts statement expressing a preference for use of thimerosal-free DTaP, Hib, and Hep B vaccines by March 2002 Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders

OCR for page 187
Immunization Safety Review: Vaccines and Autism Year Vaccine Licensure Legislation and/or Policy Statements IOM Reports on Vaccine Safety 2002     Immunization Safety Review: Multiple Immunizations and Immune Dysfunction Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer 2003 Live attenuated intranasal influenza vaccine approved for use in the United States in healthy individuals aged 5-49 years old (FluMist) ACIP recommends that children 6 to 23 months of age be vaccinated annually against influenza beginning in the 2004-2005 influenza season Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer Immunization Safety Review: Vaccinations and Sudden Unexpected Death in Infancy 2004     Immunization Safety Review: Influenza Vaccines and Neurological Complications